Financial Performance - Revenue for the three months ended September 30, 2024, was $4.448 million, an increase from $3.678 million for the same period in 2023, representing a growth of 20.9%[16] - Total costs and expenses for the three months ended September 30, 2024, were $33.637 million, compared to $18.569 million for the same period in 2023, reflecting an increase of 81.1%[16] - The net loss for the three months ended September 30, 2024, was $23.155 million, compared to a net loss of $15.790 million for the same period in 2023, representing an increase in loss of 46.7%[16] - The company reported a loss from operations of $29.189 million for the three months ended September 30, 2024, compared to a loss of $14.891 million in the same period last year, indicating a deterioration of 96.1%[16] - Net loss for the nine months ended September 30, 2024, was $92,025,000, compared to a net loss of $51,052,000 for the same period in 2023[20] Expenses - Research and development expenses for the three months ended September 30, 2024, were $11.890 million, up from $7.440 million in the same period last year, indicating a rise of 59.5%[16] - General and administrative expenses for the three months ended September 30, 2024, were $20.182 million, compared to $10.559 million in the prior year, marking an increase of 91.5%[16] - Stock-based compensation increased to $13,777,000 for the nine months ended September 30, 2024, from $7,538,000 in the prior year[20] - Stock-based compensation expense for the nine months ended September 30, 2024, was $13.8 million, up from $7.5 million for the same period in 2023[98] Cash and Equity - Cash and cash equivalents at the end of the period were $204,368,000, significantly up from $76,225,000 at the end of September 30, 2023[20] - The company’s additional paid-in capital increased to $631,556,000 as of September 30, 2024, from $560,614,000 as of June 30, 2024[18] - The total stockholders' equity as of June 30, 2024, was $62,722,000, an increase from $47,293,000 as of December 31, 2023[18] Investments and Financing - Proceeds from the sale of common stock, net of issuance costs, amounted to $138,893,000 during the nine months ended September 30, 2024[20] - The company raised approximately $53.7 million from a public offering and $10.0 million from a private offering on September 12, 2024[35] - The company entered into a Fifth Amendment to the Revenue Interest Financing Agreement, receiving an additional $32.5 million, totaling $100 million in funding[34] Research and Development - The company anticipates continued investment in research and development to support future product candidates and market expansion[8] - The company is focused on developing treatments for rare cardiopulmonary diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)[22] - The company is developing L606, an investigational liposomal formulation of treprostinil, currently in an open-label study for PAH and PH-ILD[26] - The company capitalized costs of $7.4 million associated with the production of YUTREPIA, anticipating regulatory approval and future economic benefits[70] Legal Matters - The company is currently involved in ongoing litigation with United Therapeutics, which may impact future operations and financial performance[9] - The Indemnification Asset related to the RareGen litigation is expected to increase due to ongoing legal expenses, with a conclusion unlikely before September 30, 2025[78] - The Company filed a lawsuit in the D.C. District Court challenging the FDA's decision to grant three-year regulatory exclusivity to Tyvaso DPI, with a summary judgment hearing scheduled for December 5, 2024[151] - The Company is involved in ongoing litigation regarding antitrust claims related to the drug treprostinil, with a settlement agreement reached in 2021[156] Operational Commitments - The company has non-cancelable commitments for product manufacturing and supply costs of approximately $14.7 million[142] - The company has a multi-year supply agreement with LGM Pharma, LLC, requiring a minimum annual purchase commitment of $2.7 million for active pharmaceutical ingredients for YUTREPIA[141] - The company has entered into a Device Development and Supply Agreement with Mainbridge Health Partners to develop a new pump for subcutaneous administration of Treprostinil Injection[132] Stock and Options - The fair value of stock options as of September 30, 2024, was reported at 9,113,427, compared to 9,573,680 as of December 31, 2023[66] - As of September 30, 2024, the company had 9,049,858 outstanding stock options with a weighted average exercise price of $4.76 and an aggregate intrinsic value of $47.835 million[103] - The company granted 2,146,517 restricted stock units (RSUs) during the nine months ended September 30, 2024, with a weighted average grant-date fair value of $12.57 per RSU[106] Revenue Recognition - Revenue is recognized in accordance with ASC 606, reflecting the transfer of promised goods or services to customers[54] - Approximately 98% of revenue during the three and nine months ended September 30, 2024, was generated from the Promotion Agreement with Sandoz[108]

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appealStrengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov. 13, 2024 (GLOBE ...

Liquidia Technologies, Inc. (LQDA) shares soared 11.2% in the last trading session to close at $11.15. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% gain over the past four weeks. The sudden rise in the stock price was observed after the United States Supreme Court ruled in favour of Liquidia stating that its pulmonary hypertension treatment powder, Yutrepia, does not infringe upon United Therapeutics' '793 Patent for Tyv ...

Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere Liquidia also obtains rights to Pharmosa's next-generation nebulizers for use with L606 Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America MORRISVILLE, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare ...

MORRISVILLE, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston. Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: "Every year, CHEST unites the next generation of medical p ...

Core Viewpoint - Liquidia Corporation has achieved a significant legal victory against United Therapeutics, with the court ruling that United Therapeutics' interference with the launch of generic Treprostinil Injection resulted in losses exceeding $137 million for Liquidia [1][3]. Group 1: Legal Proceedings - The United States District Court for the District of New Jersey found United Therapeutics liable for its actions that interfered with the launch of generic Treprostinil Injection, which is manufactured by Sandoz Inc. [1][2] - Liquidia PAH and Sandoz filed a lawsuit in April 2019, alleging violations of the Sherman Antitrust Act and other unfair competition statutes by United Therapeutics [2][3]. - The court's decision determined that damages caused by United Therapeutics' breach of contract exceeded $137 million, although the final damage award is still pending [3]. Group 2: Financial Implications - Under the agreement between Sandoz and Liquidia PAH, any proceeds from the litigation will be split evenly between the two companies [4]. - Liquidia PAH has entered into litigation finance agreements with Henderson SPV, LLC and PBM RG Holdings, LLC, meaning that any net proceeds from the damage award will be distributed to these parties, leaving Liquidia PAH with no retained proceeds [4]. Group 3: Product Information - Treprostinil Injection is the first-to-file, fully substitutable generic version of treprostinil for parenteral administration, offering the same active ingredients and dosage forms as the branded drug Remodulin® but at a lower price [5]. - Liquidia PAH, in partnership with Sandoz, promotes the appropriate use of Treprostinil Injection for treating pulmonary arterial hypertension (PAH) in the United States [5][6]. Group 4: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a current emphasis on pulmonary hypertension and applications of its proprietary PRINT® Technology [6]. - The company is also developing other formulations of treprostinil, including YUTREPIA™ and L606, while marketing generic Treprostinil Injection [6].

Liquidia Technologies, Inc. (LQDA) shares rallied 14.1% in the last trading session to close at $10.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 33% loss over the past four weeks. The sudden rise in the stock price was observed after Liquidia announced the pricing of an underwritten public offering and a concurrent private placement which is expected to raise gross proceeds of approximately $67.5 milli ...

MORRISVILLE, N.C., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (the "Company" or "Liquidia"), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately $67.5 million, before deducting underwriting discounts and commissions, and expenses. The Company offered 6,460,674 shares of co ...

Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's primary focus includes the development and commercialization of products for pulmonary hypertension and other applications of its proprietary PRINT® Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, which is an investigational drug for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and markets generic Treprostinil Injection for PAH treatment [3] Upcoming Events - Liquidia Corporation will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, from 11:00 – 11:35 a.m. ET [1] - The company will also present at the 2024 Cantor Global Healthcare Conference in New York on September 19, 2024, from 1:30 – 1:50 p.m. ET [1] - Access to the webcasts of these presentations will be available on Liquidia's website [1] Additional Information - An archived version of each presentation will be available on Liquidia's website for at least 30 days following the events [2]

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) on behalf of Liquidia stockholders. Our investigation concerns whether Liquidia has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 19, 2024, Liquidia issued a press release announcing ...